Australiafda

Eli Lilly & Co. is buying three clinical-stage vaccine developers for as much as $3.8 billion as it looks to become a leader in infectious diseases. The drugmaker has been using cash from its obesity drugs to expand into other disease areas. Bloomberg's Gerry Smith reports.

President Donald Trump plans to fire FDA Commissioner Marty Makary, following months of chaos at one of the country's most important health agencies, according to a person familiar with the matter. Jeff Mason has more.

Pfizer Inc. Chief Executive Officer Albert Bourla says President Donald Trump's nominee to lead the Centers for Disease Control and Prevention is a good choice. Bourla says Erica Schwartz is a "very credible scientist." Bourla also talks about earnings, their drug pipeline and doing business in China. He speaks to Bloomberg's David Westin.

The US Justice Department is expected to reclassify marijuana into a less restrictive federal category as soon as Wednesday, according to a person familiar with the matter. The change could remove taxes for companies that sell marijuana. Shares of cannabis stocks rose on the news. Nathan Dean of Bloomberg Intelligence has more.

FDA Commissioner Dr. Marty Makary discusses President Trump's Executive Order aimed at faster research and access to psychedelics, citing promising research and calling this an 'historic moment.' He talks with Romaine Bostick and Katie Greifeld on "The Close."

Jamey Millar, executive vice president, US operations of Novo Nordisk, reacts to Eli Lilly's once-daily weight-loss pill, called Foundayo, winning FDA approval on "Bloomberg The Close."

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly's tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest."